Table 2.
Subgroup analyses stratified by TNFi types and assay methods for ADAb detection.
| Group or subgroup | 3 months | 6 months | 12 months | ≥24 months | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | Model | OR (95% CI) | n | Model | OR (95% CI) | n | Model | OR (95% CI) | n | Model | OR (95% CI) | |
| Total | 3 | F | 0.03 (0.01, 0.13) | 5 | R | 0.04 (0.01, 0.22) | 6 | R | 0.26 (0.11, 0.57) | 2 | F | 0.16 (0.08, 0.33) |
|
| ||||||||||||
| TNFi | ||||||||||||
| ADAL | 2 | F | 0.02 (0.00, 0.21) | 3 | R | 0.02 (0.00, 0.62) | 1 | — | 0.06 (0.01, 0.34) | 1 | — | 0.18 (0.08, 0.38) |
| INF | 1 | — | 0.05 (0.01, 0.27) | 2 | R | 0.05 (0.00, 1.06) | 4 | F | 0.49 (0.29, 0.81) | 1 | — | 0.11 (0.02, 0.58) |
| Combine | NA | NA | NA | NA | NA | NA | 1 | — | 0.18 (0.05, 0.58) | NA | NA | NA |
|
| ||||||||||||
| Assay | ||||||||||||
| RIA | 2 | F | 0.03 (0.01, 0.11) | 3 | R | 0.02 (0.00, 0.63) | NA | NA | NA | 1 | — | 0.18 (0.08, 0.38) |
| ELISA | 1 | — | 0.10 (0.01, 2.41) | 2 | R | 0.05 (0.00, 1.13) | 5 | F | 0.20 (0.10, 0.38) | 1 | — | 0.11 (0.02, 0.58) |
| IMPACT | NA | NA | NA | NA | NA | NA | 1 | — | 0.66 (0.35, 1.24) | NA | NA | NA |
TNFi: tumor necrosis factor inhibitors; ADAL: adalimumab; INF: infliximab; ETN: etanercept; combine: INF/ETN/ADAL; OR: odds ratio; CI: confidence interval; R: randomized-effects model; F: fixed-effects model; —: no model was used; NA: not available; ELISA: enzyme-linked immunosorbent assay; RIA: radioimmunoassay; IMPACT: Immunological Multi-Parameter Chip Technology.